Business Acquisition Medix Biochemica Takes Over Molecular Diagnostics Raw Materials Manufacturing Firm
Medix Biochemica has acquired the Germany-based manufacturer of innovative and high-quality raw materials in molecular diagnostics – Mypols Biotec. The move is in line with the company’s aim of expanding its reagent offerings for molecular diagnostics as well as supports the firm’s portfolio of in vitro diagnostics raw materials.
Espoo/Finland – Medix Biochemica, a global leader in critical IVD raw materials, has acquired 100 percent of the shares of Mypols Biotec. As a result of the acquisition, Medix Biochemica broadens its portfolio of molecular diagnostic raw materials for the in vitro diagnostics (IVD) industry, complements its scientific expertise and strengthens its local presence in Western Europe. Mypols Biotec will form a significant part of the newly established Molecular Diagnostics Business Unit within Medix Biochemica Group, and its high-quality operations will continue in Konstanz, Germany. All founders of the company will remain involved in the business following the acquisition.
“This acquisition is a great step towards our vision to be the first-choice, independent raw material partner for the IVD industry, and it further accelerates Medix Biochemica’s growth in molecular diagnostics reagents business which is a key strategic expansion area for us. The broad portfolio of Mypols Biotec, including unique and innovative molecular diagnostics reagents, complements Medix Biochemica’s existing molecular diagnostics offering. With Mypols technology, we enable customers to shorten their assay development time and complexity, and perform molecular testing directly from crude samples. We will offer more flexibility in assay development by partnering in custom development projects. We are excited about the opportunity to offer these molecular diagnostics products to our global customer base,” says Steve Ferguson, CEO of Medix Biochemica.